Brief: Eli Lilly and Merck expand immuno-oncology collaboration

Procter & Gamble Health

11/01/2017 11:45

Jan 11 (Reuters) - Eli Lilly And Co  LLY.N  
    * Lilly and Merck expand immuno-oncology collaboration 
    * Eli Lilly and co - financial details of collaboration were 
not disclosed. 
    * Lilly is sponsor of Phase 1 study and enrollment is 
expected to begin mid-2017. 
    * Eli Lilly - expansion of collaboration with Merck to add 
new study of lartruvo with keytruda in patients with previously 
treated soft tissue sarcoma 
 
Source text for Eikon:  ID:nPn4ngmf3a  
Further company coverage:  LLY.N  
 
 ((Bangalore.newsroom@thomsonreuters.com;))